Synthetic probes of glycosaminoglycan function by Griffin, Matthew E. & Hsieh-Wilson, Linda C.
Synthetic Probes of Glycosaminoglycan Function
Matthew E Griffin and Linda C Hsieh-Wilson1
Division of Chemistry and Chemical Engineering and Howard Hughes Medical Institute, California
Institute of Technology, Pasadena, CA 91125, USA
Abstract
Glycosaminoglycans participate in many critical biological processes by modulating the activities
of a wide range of proteins, including growth factors, chemokines, and viral receptors. Recent
studies using synthetic oligosaccharides and glycomimetic polymers have established the
importance of specific structural determinants in controlling glycosaminoglycan function. These
findings illustrate the power of synthetic molecules to elucidate glycan-mediated signaling events,
as well as the prospect of further advancements to understand the roles of glycosaminoglycans in
vivo and explore their therapeutic potential.
Introduction
Glycosaminoglycans (GAGs) are a class of highly charged, extracellular polysaccharides
that display rich structural diversity [1,2]. The two most prevalent members of the family,
heparin/heparan sulfate (HS) and chondroitin sulfate (CS), are composed of repeating
disaccharide units of uronic acid (L-iduronic acid or D-glucuronic acid) and hexosamine (D-
glucosamine or D-galactosamine) sugars (Figure 1A). Each sugar is differentially sulfated at
the hydroxyl and/or amino positions by various sulfotransferase enzymes, giving rise to
hundreds of potential sulfation sequences. This structural diversity leads to a wide range of
protein-binding motifs and enables modulation of cellular signaling pathways. Indeed,
GAGs participate in many important signaling events such as neuronal growth [2–5], tumor
progression [6], inflammation [7], and development [8]. Their involvement in both normal
and disease-related processes has sparked intense interest in understanding the mechanisms
and structural determinants that control GAG activity. However, the chemical complexity
and diversity of these polysaccharides present a formidable challenge to elucidating their
structure-function relationships.
A major barrier to understanding GAGs has been the difficulty of accessing defined
structures. Well-characterized, homogeneous GAG fragments are challenging to purify from
natural sources due to their strong anionic character and assorted sulfation patterns. Purified
structures are usually limited to the most abundant sulfation sequences and lack the rare,
highly sulfated epitopes that are often physiologically important. Chemically modified
heparin/HS polysaccharides and CS motif-enriched polysaccharides typically contain a
small percentage of other sulfated epitopes that can also exert biological activity. As such,
caution must be used when interpreting results obtained with natural GAGs. From a purity
and selectivity standpoint, these limitations make the use of defined synthetic structures
crucial for studying the structure-function relationships of GAGs.
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In this article, we describe some of the recent advances in the synthesis of GAG
oligosaccharides and glycomimetic polymers. These advances include both synthetic
organic and chemoenzymatic approaches to access defined oligosaccharides and
polymerization techniques to develop simplified glycomimetics that emulate the natural
multivalency of GAGs. We also highlight how these molecules have been used as probes to
identify the roles of specific sulfation motifs in mediating key signaling events and cellular
processes. Together, the studies suggest opportunities for the continued development of new
chemical approaches to interrogate the functions of this ubiquitous, important class of
polysaccharides.
Chemical synthesis of GAG oligosaccharides
The chemical synthesis of GAGs is notoriously challenging because it requires iterative,
stereoselective formation of glycosidic bonds and sophisticated protecting group strategies
to achieve regioselective sulfation [9–17]. Many syntheses employ a modular, convergent
approach in which a core oligosaccharide is assembled from a common disaccharide
precursor. A late divergent approach is then exploited to differentially deprotect and
regioselectively sulfate the core oligosaccharide and produce compounds with specific
sulfation motifs.
A major challenge remains the generation of diverse libraries of GAG oligosaccharides with
defined structures. To date, only a relatively small proportion of the theoretically possible
structures have been synthesized. However, new methods have emerged that may accelerate
the generation of comprehensive collections of defined GAG oligosaccharides. For example,
Jacquinet and coworkers developed efficient syntheses of CS tetra- and hexasaccharides
bearing the CS-A, -C, -D, -E, -K, -L, and -M sulfation motifs using a precursor derived from
natural CS polysaccharides [18–20]. Their method exploited the controlled hydrolysis of
commercially available CS to rapidly and inexpensively obtain a fully-protected
disaccharide building block. More recently, Seeberger and coworkers reported a solid-phase
synthesis of CS oligosaccharides [21]. By attachment to Merrifield resin, many of the
arduous purification steps associated with carbohydrate synthesis were avoided. The
growing oligosaccharides were elongated by the sequential addition of monosaccharide
phosphate donors and were selectively deprotected and sulfated over the course of three
days to produce CS-A and CS-C hexasaccharides with an average yield of 86–88% per step.
These methods may help expedite the development of much needed structure libraries that
encompass a larger proportion of the molecular diversity found in GAGs.
The joint venture of chemical synthesis and biological studies can have an enormous impact
on our understanding of GAGs and their roles in physiological processes. The quintessential
illustration of the power of this combined approach is demonstrated by the pioneering
studies of Petitou, Sinaÿ, Choay, Lindahl and others, whose investigations in the late 1970s
and early 1980s led to the discovery of a specific pentasaccharide within heparin that is
responsible for its anticoagulant activity (Figure 1B) [22–24]. Their work provided critical
insights into heparin’s mechanism of action and facilitated the development of the
pentasaccharide drug Arixtra (GlaxoSmithKline).
More recently, de Paz et al. studied the interactions of various synthetic heparin
oligosaccharides with chemokines, a large family of proteins involved in injury,
inflammation, and atherosclerosis [25]. Various mono-, di-, tetra-, and hexasaccharides with
natural and non-natural sulfation motifs were synthesized with amine-terminated linkers to
allow for the generation of glycan microarrays. The authors rapidly screened the affinities of
various chemokines for twelve oligosaccharides, revealing patterns of binding strengths that
depended on individual sulfate groups. Notably, different chemokines displayed preferences
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for different sulfation patterns. For example, CCL21 exhibited robust binding to tetra- and
hexasaccharides containing at least two sulfate groups per disaccharide, whereas CXCL13
and CCL19 showed weak or no binding to the same structures. This study demonstrates that
synthetic oligosaccharides, when combined with glycan microarrays, can be used to rapidly
assess the role of individual sulfation patterns in mediating GAG-protein interactions.
Further development of comprehensive libraries of synthetic GAGs may lead to elucidation
of the exact structural requirements for HS recognition by different chemokines.
The effects of HS sulfation pattern and chain length on cytokine-dependent angiogenic
functions were examined by Cole et al. using a series of synthetic oligosaccharides [26].
Compounds ranging in length from seven to twelve sugar units and containing a repeating
disaccharide unit of 2-O-sulfated iduronate with or without N-sulfated glucosamine (2S or
2SNS) were tested for their ability to compete with HS for binding to fibroblast growth
factor 2 (FGF-2) and vascular endothelial growth factor 165 (VEGF165) (Figure 2A). A
strong correlation was found between the oligosaccharide structures, their affinity for the
cytokines, and their ability to inhibit specific cytokine-dependent functions such as
endothelial cell migration and tube formation. The 2SNS decasaccharide and
dodecasaccharide showed the most potency overall, whereas the 2SNS heptasaccharide and
all 2S oligosaccharides had no significant effect. This work represents one of the most
systematic structure-function studies to date using synthetic HS oligosaccharides, and the
results suggest that important cytokine-mediated cell functions depend highly on the fine
structure of HS.
Hu et al. recently studied the role of specific HS sulfation motifs in herpes simplex virus
type 1 (HSV-1) infection using synthetic oligosaccharides [27]. HSV-1 attachment and entry
into host cells is mediated by the binding of several viral envelope glycoproteins to HS
chains on the host cell surface. One glycoprotein, gD, binds specifically to HS modified with
the rare 3-O-sulfate motif [28]. In this study, the authors completed an impressive synthesis
of two non-repeating, gD-binding HS octasaccharides that contained the 3-O-sulfate epitope
at different sites (Figure 2B). Their synthetic route made use of a key disaccharide
intermediate to acquire the different building blocks required for oligosaccharide assembly.
Both molecules prevented HSV-1 infection of Vero cells in a dosage-dependent manner,
presumably by blocking the binding of gD to endogenous HS. In contrast, commercially
available HS from natural sources failed to prevent HSV-1 infection. These studies suggest
flexibility in designing 3-O-sulfate-containing HS oligosaccharides as anti-HSV-1 agents
and demonstrate the potential for defined synthetic molecules to reveal insights into the
mechanisms of viral-host cell infection.
Like HS, CS has been shown to engage protein receptors and facilitate important cellular
signaling events. The first investigations using synthetic oligosaccharides to study the
activity of CS sulfation motifs were reported by Gama et al. [16]. A late divergent synthetic
strategy was developed to produce tetrasaccharides containing the CS-A, CS-C, and CS-E
sulfation motifs, as well as a non-natural, highly sulfated motif (CS-R; Figure 2C). Although
the CS-E and CS-R tetrasaccharides contained the same number of sulfate groups, only the
CS-E tetrasaccharide modulated the outgrowth of developing neurons. The authors found
that the growth-promoting activity was primarily due to the interaction of CS-E with specific
growth factors, including brain-derived neurotrophic factor (BDNF) and midkine.
Subsequent studies using a combination of glycan microarrays, computational modeling,
and cellular assays showed that the CS-E motif is capable of forming a multimeric protein
complex between BDNF and its cell surface receptors, thereby modulating neurotrophin
signaling pathways [29]. Together, these results demonstrate that the specific sulfation
sequence – namely, the precise position of the sulfate groups along the carbohydrate
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backbone and not merely electrostatics alone – can modulate GAG-protein interactions and
direct important neuronal signaling events.
These examples highlight the power of synthetic oligosaccharides to recapitulate the activity
of natural GAG polysaccharides in a variety of biological contexts. The ability to access
defined sulfation sequences instead of relying on the average, bulk properties of natural
polysaccharides enables functions to be assigned to specific sulfation motifs. Such structure-
function analyses have provided meaningful mechanistic insights into important biological
processes and may provide novel therapeutic opportunities, as exemplified by Arixtra.
Chemoenzymatic approaches to defined GAG oligosaccharides
Exploiting natural GAG processing enzymes to obtain defined structures represents a
complementary approach to the chemical synthesis of GAGs. Such chemoenzymatic
methods utilize glycosyltransferases to produce oligosaccharides of defined length, followed
by sulfotransferases for regioselective sulfation. These approaches can streamline the
synthesis by circumventing the requirement for stereoselective glycosylation reactions and
sophisticated protecting group strategies.
A beautiful series of studies by Rosenberg, Liu, Linhardt, and coworkers has illustrated the
potential of chemoenzymatic approaches to GAGs. Investigations into the specificity and
activity of various HS polymerase, sulfotransferase, and epimerase enzymes have allowed
for the synthesis of defined heparin oligosaccharides with potent anticoagulant properties
[30–35]. While pioneering methods produced an antithrombin III-binding pentasaccharide
on a microgram scale [34], recent work substantially improved on the approach to generate
two ultralow-molecular-weight heptasaccharides in 10–12 steps (>95% purity, 38% overall
yield) on up to a 50-milligram scale (Figure 3) [35]. The heptasaccharides exhibited strong
anticoagulant factor Xa activity with potencies comparable to the pentasaccharide drug
Arixtra, which requires approximately 50 chemical steps and affords only a 0.1% overall
yield [36]. Although industrial-scale syntheses must still be developed, these impressive
studies demonstrate that the efficient chemoenzymatic synthesis of defined, therapeutically
important GAG structures is now possible.
Recent efforts have also focused on chemoenzymatic methods to produce CS
oligosaccharides and polysaccharides. Unsulfated chondroitin oligomers were assembled by
generating two partial loss-of-function mutants of the bifunctional chondroitin polymerase
(K4CP) to isolate the individual glycosyltransferase activities [37]. Alternating application
of each enzyme immobilized on agarose beads extended a pyridylamine-functionalized CS
trisaccharide substrate to produce an unsulfated CS 16-mer. In another study, wild-type
K4CP was used to generate a 10-kDa unsulfated chondroitin polymer starting from a
hexasaccharide acceptor substrate, which was then treated with various sulfotransferases
(C4ST-1, C6ST-1, GalNAc4S-6ST, and UA2ST) to produce sulfated CS libraries that were
more highly enriched in particular sulfation motifs than their natural counterparts [38]. For
example, the artificial CS-E polysaccharide contained 88% of the CS-E disaccharide unit,
compared to 64% found in purified CS-E enriched polysaccharides. Moreover, the approach
generated unsulfated, CS-A, and CS-C polysaccharides, with no detectable amounts of the
more highly sulfated motifs that contaminate natural polysaccharides and can complicate
structure-function analyses. These chemoenzymatically-synthesized polysaccharides,
although still only enriched in particular motifs, will provide valuable tools for studying the
physiological functions of specific CS sulfation motifs. Additionally, this work suggests that
the success of chemoenzymatic approaches to defined heparin/HS oligosaccharides also
should be amenable to CS.
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Glycomimetic GAG polymers
Despite significant advances in the synthesis of GAGs, access to longer oligosaccharides of
single, defined structure and varied sulfation sequence remains a central challenge. Longer
oligosaccharides are often required for full biological activity [1,23], and comprehensive
collections of GAG oligosaccharides that represent all of the theoretically possible sulfation
sequences cannot be obtained using current technologies. Overcoming these challenges will
be required to understand fully the specificity of GAG interactions and to develop selective
GAG-targeting agents. To address these issues, recent studies have exploited polymerization
techniques to generate synthetic glycopolymers that present short, defined sulfation motifs
within multivalent frameworks to recapitulate the activity of longer oligosaccharides.
Seeberger and coworkers have functionalized starburst polyamidoamine (PAMAM)
dendrimers containing 32 terminal carboxylate groups with amine-terminated heparin
mono-, di-, and hexasaccharides (Figure 4A) [39]. Twenty-five percent loading (eight
saccharide monomers appended) was achieved, which was attributed to steric hindrance or
electrostatic repulsion between the negatively charged saccharides and PAMAM cores.
Nonetheless, the glycodendrimers competed with heparin for binding to FGF-2 and
stimulated downstream extracellular signal-regulated kinase (ERK) phosphorylation better
than the corresponding monovalent hexasaccharide. In another study, de Paz et al. showed
that the same hexasaccharide glycodendrimer inhibited CCL21-mediated chemotaxis,
whereas the monomeric hexasaccharide had no significant effect [25]. Interestingly, the
monomeric hexasaccharide containing three sulfates per disaccharide exhibited stronger
binding to CCL21 when compared to other sulfation epitopes. These findings underscore the
importance of both the sulfation sequence and multivalency in eliciting HS-mediated
responses.
Hsieh-Wilson and coworkers have utilized ring-opening metathesis polymerization (ROMP)
chemistry to synthesize both CS and heparin/HS glycopolymers [5,40–42]. Fully-protected
CS-E di- and tetrasaccharides containing cis-cyclooctene or norbornene groups were
polymerized using the fast-initiating ruthenium catalyst (H2IMes)(Py)2(Cl)2Ru=CHPh to
generate a series of CS polymers, which were subsequently deprotected (Figure 4B)
[5,40,41]. Varying the amount of catalyst allowed for excellent control of the degree of
polymerization, affording polymers with 25 to 100 sugar units attached. Notably, the
glycopolymers displayed robust activity comparable to natural CS-E polysaccharides in
neurite outgrowth assays [40]. The activity was polymer length-dependent, while
monovalent di- and tetrasaccharides had minimal activity, highlighting the importance of
multivalency and the tunability of the synthetic polymers. Lee et al. later showed that
glycopolymers made from norbornenyl-functionalized CS-E disaccharides could be end-
functionalized with a biotin moiety to afford a handle for microarray and surface plasmon
resonance studies [41]. More recently, the approach was expanded by Brown et al. to
generate glycopolymers displaying different sulfation motifs (CS-A, -C, and -E) for
structure-function analyses [5]. Only glycopolymers containing the CS-E motif inhibited the
outgrowth of adult sensory neurons and induced growth cone collapse. These results,
combined with additional biological studies, linked the specific CS-E sulfation epitope to the
inhibition of axon regeneration after spinal cord and other neuronal injuries. Indeed,
blocking the CS-E structure with an antibody raised against a synthetic CS-E tetrasaccharide
promoted optic nerve regeneration in vivo, suggesting a new potential strategy for neuronal
repair.
In addition to providing functional insights, glycomimetic polymers have shown promise as
agents for modulating GAG activity, which may be therapeutically beneficial in many
contexts. For example, heparin possesses potent anti-inflammatory activity in models of
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asthma, chronic dermatitis, and ulcerative colitis, but it is not recommended as an anti-
inflammatory agent in clinical practice due to its anti-coagulant activity [43]. Sheng et al.
synthesized a variety of differentially sulfated HS glycopolymers from a core disaccharide
precursor using ROMP chemistry (Figure 4C) [42]. A specific glycopolymer bearing a
trisulfated HS epitope antagonized the proinflammatory chemokine RANTES and blocked
RANTES-induced cell migration with potencies comparable to heparin. Remarkably, the
glycopolymer, which lacked the 3-O-sulfate modification, failed to inhibit key serine
proteases in the blood coagulation cascade. Thus, controlling the positioning of sulfate
groups within the glycopolymer enabled the anti-inflammatory properties of heparin/HS to
be dissected from its anticoagulant properties. Given the pleiotropic functions of heparin/
HS, such a strategy may allow for the development of more selective GAG-based
therapeutic agents with fewer off-target side effects.
More recently, anticoagulant heparin-based glycopolymers were generated containing a
tetrasulfated disaccharide epitope designed from Arixtra (Y-I Oh et al., unpublished). The
ROMP-generated glycopolymers exhibited potent anti-factor Xa and anti-thrombin activity
and prolonged blood-clotting times in human plasma with efficacies similar to those of the
clinical anticoagulants heparin, low-molecular-weight heparin (LMWH), and Arixtra.
Whereas short polymers (15 disaccharide units) displayed ex vivo clotting times similar to
Arixtra, longer glycopolymers (30 and 45 disaccharide units) displayed unique hybrid
properties, with activated partial thromboplastin times similar to LMWH and Arixtra and
prothrombin times similar to heparin. These studies not only suggest glycopolymers as a
potential new anticoagulant therapeutic agent, but also raise the possibility that fine-tuning
the polymer structure may produce novel agents with properties distinct from both synthetic
and natural GAGs.
Conclusions and future directions
Synthetic GAG oligosaccharides and glycomimetic polymers have provided mechanistic
insights into important biological processes, and an understanding of the structure-function
relationships of this class of polysaccharides has begun to emerge. Through the use of
defined synthetic molecules, specific sulfation motifs have been linked to diverse
physiological outcomes. The participation of GAGs in myriad processes, ranging from
inflammation and axon regeneration to viral infection, underscores the biological importance
of these molecules and their future potential as therapeutic targets.
The continued development of novel methods to synthesize GAG oligosaccharides and
polymers will be essential to delineate further the structure-function relationships and
develop ways to selectively target specific GAG-mediated events. In particular, the
construction of GAG libraries that encompass a larger swath of the sulfation sequence space
will be important and may be facilitated in the future by automation and solid-phase
methods [44,45]. Advances in pathway bioengineering [46] and directed evolution [47] may
enable further improvements in the chemoenzymatic synthesis of GAGs, allowing for
streamlined syntheses, larger scale production, as well as microbial factories [48] for
producing collections of defined GAG structures. Finally, the development of simplified
GAG mimetics capable of targeting specific GAG-protein interactions in vivo may be
possible in the future through the systematic exploration of different polymer architectures.
Ultimately, this synergistic combination of organic chemistry and biology will provide new
opportunities to elucidate important physiological processes and to exploit this knowledge
for diverse therapeutic applications.
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Highlights
• Synthetic oligosaccharides help link specific structures to biological processes
• Chemoenzymatic methods can now produce therapeutically active
oligosaccharides
• Biomimetic polymers enable modulation of GAG-mediated biological events
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Figure 1.
The structural diversity of GAGs. (a) Representative GAGs heparin/HS and CS, with
potential sites of sulfation indicated. Ac = acetyl. (b) Bioactive sulfation sequences such as
the Arixtra pentasaccharide are found within the heterogeneous structure of GAG
polysaccharides.
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Figure 2.
Synthetic oligosaccharides for studying the diverse biological functions of GAGs. (a)
Oligosaccharides used to study the effects of HS sulfation pattern and chain length on
cytokine-dependent angiogenic functions. Longer oligosaccharides containing both the 2-O-
and N-sulfation inhibited FGF-2-mediated endothelial tube formation. (b) HS
octasaccharides containing the rare 3-O-sulfate group prevented HSV-1 infection of Vero
cells. TBDPS = tert-butyldiphenylsilyl, 2-NAP = 2-naphthylmethyl, PBB = p-bromobenzyl,
Bn = benzyl, Bz = benzoyl. (c) Synthetic CS tetrasaccharides used to demonstrate sulfation
sequence-specific effects on the outgrowth of developing neurons. All = allyl.
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Figure 3.
Chemoenzymatic synthesis of defined heparin therapeutics. A bioactive heptasaccharide
mimic of the anticoagulant drug Arixtra was produced in twelve steps on a milligram scale.
KfiA = N-acetyl glucosaminyl transferase, UDP-GlcNTFA = uridine diphosphate N-
trifluoroacetylglucosamine, pmHS2 = heparosan synthase-2, UDP-GlcUA = uridine
diphosphate glucuronic acid, TEA = triethylamine, NST = N-sulfotransferase, PAPS = 3′-
phosphoadenosine 5′-phosphosulfate, C5-epi = C5-epimerase, 2-OST = 2-O-sulfotransferase,
6-OST = 6-O-sulfotransferase, 3-OST-1 = 3-O-sulfotransferase isoform 1.
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Figure 4.
Glycomimetic GAG polymers. (a) A PAMAM dendrimer functionalized with a synthetic
HS hexasaccharide interact with FGF-2 and stimulate ERK signaling. (b) CS polymers
generated by ROMP allow for presentation of multiple sulfation epitopes and chain length
control. The CS-E glycopolymers showed activities comparable to natural CS-E
polysaccharides in both neurite outgrowth and growth cone collapse assays. (c) ROMP-
based HS polymers used to study the role of sulfation in modulating chemokine activity.
Trisulfated polymer 1 selectively inhibited the chemokine RANTES without targeting
proteins in the blood coagulation cascade. TBS = tert-butyldimethylsilyl, Lev = levulinoyl.
Griffin and Hsieh-Wilson Page 14
Curr Opin Chem Biol. Author manuscript; available in PMC 2014 June 01.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
